<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:media="http://search.yahoo.com/mrss/"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>hims &amp; hers Archives - The Daily Update</title>
	<atom:link href="https://thedailyupdate.co/tag/hims-hers/feed/" rel="self" type="application/rss+xml" />
	<link>https://thedailyupdate.co/tag/hims-hers/</link>
	<description>Stay ahead with daily news, insights, and trends that matter</description>
	<lastBuildDate>Thu, 19 Nov 2026 10:23:23 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.1.5</generator>

<image>
	<url>https://thedailyupdate.co/wp-content/uploads/2026/03/cropped-thedailyupdate_logo-32x32.png</url>
	<title>hims &amp; hers Archives - The Daily Update</title>
	<link>https://thedailyupdate.co/tag/hims-hers/</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>Hims &#038; Hers Launches Peptides+ With Five Unapproved Compounded Treatments</title>
		<link>https://thedailyupdate.co/2026/11/19/hims-hers-launches-peptides-with-five-unapproved-compounded-treatments/</link>
		
		<dc:creator><![CDATA[admin]]></dc:creator>
		<pubDate>Thu, 19 Nov 2026 10:23:23 +0000</pubDate>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[compounded drugs]]></category>
		<category><![CDATA[hims & hers]]></category>
		<category><![CDATA[longevity treatments]]></category>
		<category><![CDATA[peptides therapy]]></category>
		<guid isPermaLink="false">https://thedailyupdate.co/2026/11/19/hims-hers-launches-peptides-with-five-unapproved-compounded-treatments/</guid>

					<description><![CDATA[<p>Hims &#38; Hers Enters the Booming Peptide Market Hims &#38; Hers Health (NYSE: HIMS) announced on Wednesday the launch of Peptides+, a new specialty built around clinically guided protocols. The platform targets health at the cellular level. However, none of the initial products carries approval from regulators. The company will offer five formulations at launch. [&#8230;]</p>
<p>The post <a href="https://thedailyupdate.co/2026/11/19/hims-hers-launches-peptides-with-five-unapproved-compounded-treatments/">Hims &#038; Hers Launches Peptides+ With Five Unapproved Compounded Treatments</a> appeared first on <a href="https://thedailyupdate.co">The Daily Update</a>.</p>
]]></description>
										<content:encoded><![CDATA[<div class="art_img_credit" data-credit="Image: AI-generated"></div>
<h2>Hims &amp; Hers Enters the Booming Peptide Market</h2>
<p><strong>Hims &amp; Hers Health</strong> (NYSE: <span class="art_cus_secondary">HIMS</span>) announced on Wednesday the launch of <strong>Peptides+</strong>, a new specialty built around clinically guided protocols. The platform targets health at the cellular level. However, none of the initial products carries approval from regulators.</p>
<p>The company will offer <span class="art_cus_primary">five formulations</span> at launch. Each one is compounded in the United States. Furthermore, Hims &amp; Hers admitted it still has more to learn about how best to use peptides and how well they work.</p>
<p>That admission <u>underscores the uncertainty</u> surrounding a fast-growing space. Peptides are short chains of amino acids. As a result, they have drawn intense interest from fitness and longevity enthusiasts.</p>
<h3>The Five Treatments at Launch</h3>
<p>Eligible customers must first complete a clinical visit with a licensed provider. The provider may then prescribe a personalized plan with up to five treatments. Specifically, the launch lineup includes the following:</p>
<ul>
<li><strong>Sermorelin:</strong> a peptide that stimulates growth-hormone release, marketed for recovery, body composition and anti-aging.</li>
<li><strong>Glutathione:</strong> a peptide promoted for anti-aging and athletic recovery.</li>
<li><strong>NAD+:</strong> a coenzyme that plays a role in cellular metabolism.</li>
<li><strong>Vitamin B-12:</strong> a vitamin needed to make red blood cells, build DNA and maintain healthy nerve function.</li>
<li><strong>L-Carnitine:</strong> an amino acid derivative that helps the body turn fat into energy.</li>
</ul>
<p>The <span class="art_cus_secondary">Food and Drug Administration</span> has approved certain prescription forms of both vitamin B-12 and L-carnitine. Those approvals cover established medical uses, primarily diagnosed deficiencies. In contrast, the company&#8217;s compounded versions do not carry FDA approval.</p>
<h3>More Peptides on the Way</h3>
<p>Hims &amp; Hers plans to add more peptides and therapies made in the U.S. over time. Among them is <strong>BPC-157</strong>, an unapproved peptide derived from a protein found in human gastric juice. Marketers promote it for healing processes.</p>
<p>The company also aims to introduce <strong>TB-500</strong>. This unapproved peptide comes from a naturally occurring protein in the body. Sellers market it for broader, systemic soft-tissue recovery and flexibility. Access to both will follow, &#8220;consistent with regulatory standards,&#8221; according to the company&#8217;s announcement.</p>
<p>Meanwhile, the evidence base remains thin. Most peptides in this category <em>lack robust human trials</em>, even though users credit them with muscle growth, rapid injury recovery and anti-aging effects.</p>
<h3>Regulatory Shift Opens the Door</h3>
<p>The launch follows a change in federal policy. The government recently <strong>eased restrictions</strong> on compounding certain unapproved peptides. Consequently, telehealth companies now see a path into a market that had relied on gray-market sellers.</p>
<p>Hims &amp; Hers says its products are legal. It describes them as authorized by law and formulated by pharmacies &#8220;that adhere to rigorous quality standards and are licensed and inspected by state boards of pharmacy.&#8221; Licensed U.S. pharmacies dispense the treatments directly to patients.</p>
<p>Demand already looks strong. The company opened an early access list in late October. Within <span class="art_cus_primary">15 days</span>, more than <span class="art_cus_primary">10,000 people</span> had signed up, a spokesperson said in a statement.</p>
<h3>How the Care Model Works</h3>
<p>Every plan begins with a comprehensive intake of health history and goals. A licensed provider trained in peptide therapies then assesses each person. If appropriate, the provider tailors a personalized protocol.</p>
<p>The care team follows up regularly and can adjust the plan as needed. The company argues that needs change over time. According to its announcement, what someone needs now may not be what they need in a year, or in ten years.</p>
<p>Hims &amp; Hers also pitches Peptides+ as an alternative to existing options. Until now, the company says, getting these medications has often meant relying on unreliable and unregulated online sellers, or paying for a high-cost longevity clinic. Therefore, it positions the service as more accessible care with consistent clinical oversight.</p>
<h3>Executives Stress Medical Oversight</h3>
<p class="article_blockquote">“Peptides+ gives men a clinically guided, personalized plan built around their goals, backed by a licensed provider who understands these therapies,” said Anant Vinjamoori, MD, MBA, Chief Medical Officer of Hims. “Anyone investing in their health deserves to know exactly what they’re putting in their body, and to have dedicated support along the way.”</p>
<p class="article_blockquote">“Women are used to being told their fatigue, brain fog, and changing bodies are simply part of life, and many have had to advocate for themselves just to be heard,” said Jessica Shepherd, MD, MBA, FACOG, Chief Medical Officer of Hers. “We believe women deserve a more comprehensive and personalized approach to their health, one that considers their unique health history, evolving needs and individual goals. The emerging therapies in Peptides+ have exciting potential.&#8221;</p>
<p>Notably, Shepherd described the therapies as <em>emerging</em>. That framing matches the company&#8217;s own caution about how much remains unknown.</p>
<h3>What It Means for Investors and Patients</h3>
<p>Shares of Hims &amp; Hers traded around <span class="art_cus_primary">$18</span> on Wednesday, up from a previous close of <span class="art_cus_primary">$17.55</span>. The stock sits well below its <span class="art_cus_primary">52-week high of $40.99</span>. Its market capitalization stands at roughly <span class="art_cus_primary">$4.25 billion</span>.</p>
<p>The company reported a trailing profit margin of <span class="art_cus_critical">-6.65%</span>. Analysts, on average, hold a one-year price target of <span class="art_cus_primary">$28.31</span>. Thus, new product lines like Peptides+ may matter for its growth story.</p>
<p>For patients, however, the key question is not financial. <strong>Compounded, unapproved products</strong> have not gone through the FDA review process. Consumers should discuss risks, benefits and the limited evidence with a licensed provider before starting any peptide therapy.</p>
<h3>A Market Still Taking Shape</h3>
<p>Peptides+ shows how quickly the longevity trend has moved into mainstream telehealth. The rollout combines consumer enthusiasm, looser federal rules and a physician-led delivery model. Even so, the science is still catching up.</p>
<p>Hims &amp; Hers operates in the <span class="art_cus_secondary">United States</span>, the <span class="art_cus_secondary">United Kingdom</span>, <span class="art_cus_secondary">Canada</span> and several other markets. Yet the Peptides+ launch applies to treatments compounded in the U.S. How the platform performs will depend on patient outcomes, regulatory developments and the strength of future research.</p>
<p>The post <a href="https://thedailyupdate.co/2026/11/19/hims-hers-launches-peptides-with-five-unapproved-compounded-treatments/">Hims &#038; Hers Launches Peptides+ With Five Unapproved Compounded Treatments</a> appeared first on <a href="https://thedailyupdate.co">The Daily Update</a>.</p>
]]></content:encoded>
					
		
		
		<media:content url="https://thedailyupdate.co/wp-content/uploads/2026/11/ai-hims-hers-launches-peptides-with-five-unapproved-c-4eddcf2b.jpg" medium="image"></media:content>
	</item>
	</channel>
</rss>
